Why in News
On November 9, the world’s first vaccine for chikungunya was approved by the Food and Drug Administration in the U.S.
The vaccine has been developed by European vaccine manufacturer Valneva.
Chikungunya, is characterised by severe joint pain and impaired mobility, and comes with fever.
It is a viral infection (CHIKV) transmitted primarily by the Aedes aegypti and Aedes albopictus mosquitoes.
Prevention includes mosquito control activities, primarily falling under public health outreach and routine civic maintenance.
What is Ixchiq
Ixchiq is a single-dose, live-attenuated vaccine for the prevention of chikungunya disease in individuals 18 years of age and older.
It was developed by Valneva SE and received FDA approval in November 2023.
Ixchiq is the world's first chikungunya vaccine to be approved for use in adults.
How Ixchiq works
Ixchiq contains a weakened version of the chikungunya virus.
Which helps to build up an immune response to the virus.
This immune response can then help to protect you from getting chikungunya disease if you are exposed to the virus in the future.
Chikungunya virus
COMMENTS